{"id":"bg00010","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Musculoskeletal pain"}]},"_chembl":{"chemblId":"CHEMBL4297910","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to amyloid beta, a protein that accumulates in the brains of people with Alzheimer's disease, thereby reducing its toxic effects. This mechanism is thought to slow the progression of the disease.","oneSentence":"BG00010 is a monoclonal antibody targeting amyloid beta.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:23.605Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT01873404","phase":"PHASE2","title":"BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-06","conditions":"Painful Lumbar Radiculopathy, Sciatica, Radiculopathy","enrollment":183},{"nctId":"NCT01842126","phase":"PHASE1","title":"Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-04","conditions":"Painful Lumbar Radiculopathy, Healthy","enrollment":54},{"nctId":"NCT00961766","phase":"PHASE1","title":"Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2009-08","conditions":"Sciatica","enrollment":48},{"nctId":"NCT01405833","phase":"PHASE1","title":"Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.","status":"COMPLETED","sponsor":"Biogen","startDate":"2011-07","conditions":"Sciatica","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Neublastin"],"phase":"phase_2","status":"active","brandName":"BG00010","genericName":"BG00010","companyName":"Biogen","companyId":"biogen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BG00010 is a monoclonal antibody targeting amyloid beta. Used for Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}